Market Intelligence, Clinical Progress, and High-Purity Reagents for Parkinson's Disease and Inflammatory Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LRRK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRRK2 Full-Length & Kinase Domain Proteins (WT, G2019S, R1441C) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View LRRK2 Products |
| Gene Delivery | LRRK2 Premade Lentivirus (Wild-Type & G2019S) Full-length ORF for stable neuronal cell lines. High titer. |
View LRRK2 Products |
| Benchmark Ab | Anti-LRRK2 (Total & Phospho-Specific) Recombinant rabbit monoclonals for Western/IP. |
View LRRK2 Products |
| Validator | LRRK2 siRNA Set (3 unique sequences) For knockdown verification in cellular assays. |
View LRRK2 Products |
| α-Synuclein (SNCA) | Aggregation pathway synergist. Critical for combination therapy models. | View SNCA Products |
| RAB8A | Primary LRRK2 substrate (GTPase). Required for substrate phosphorylation assays. | View RAB8A Products |
| PINK1 | Mitochondrial quality control pathway. Alternative PD target for pathway comparison. | View PINK1 Products |
| GBA1 | Lysosomal target with genetic links to PD. Core for GBA-LRRK2 combination strategies. | View GBA1 Products |
| Rab10 | Direct LRRK2 substrate; phosphorylation readout (pRab10) for target engagement. | View Rab10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Activity Assay (Catalytic efficiency, ATP Km) | High-specific activity LRRK2 Kinase Domain (residues 1875-2482), Sequence Verified, Theoretical MW confirmed |
| Mutation-Specific Inhibitor Screening (Gain-of-function mutants) | Disease-mutation panel: G2019S, R1441C, Y1699C vs Wild-Type. Strict mass spec identity verification |
| Cellular Model Generation (Neuronal lines) | Lentivirus particles (WT & G2019S) for stable integration in SH-SY5Y or iPSC-derived neurons |
| Off-Target Selectivity (RIPK1/3, LRRK1 cross-reactivity) | Homolog panel: LRRK1 Kinase Domain, RIPK1 available for selectivity counter-screening |
| Biomarker Detection (pS935, pS1292) | Phospho-specific antibodies with synthetic peptide validation (theoretical binding affinity) |
Live LRRK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRRK2 therapeutics has shifted from broad-spectrum kinase inhibition to mutation-aware, brain-penetrant selective inhibitors. As first-generation molecules (e.g., DNL151) advance through Phase II, the field confronts the dual challenge of achieving sufficient central exposure while avoiding peripheral toxicities—notably the lung fibrosis signals observed with less selective compounds. The next wave of R&D is targeting G2019S-specific conformational inhibitors, bifunctional degraders (PROTACs), and antisense oligonucleotides (ASOs) to address non-catalytic scaffolding functions, alongside biomarker-driven patient stratification strategies. Combination therapies with GBA modulators and α-synuclein-targeting agents are emerging as preclinical priorities.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (ATP-competitive/Allosteric) | Denali/Biogen (DNL151), Novartis | Parkinson's Disease (G2019S carriers) | Kinase Activity Assay (Need active, high-purity LRRK2 kinase domain with <5% contaminant interference) |
| PROTAC Degrader | Arvinas, C4 Therapeutics, Emerging Biotech | Neurodegeneration | Cellular Target Engagement (Need lentivirus-expressed LRRK2 for ternary complex formation assays) |
| Allosteric Modulator | Academic consortia | Leucine-rich repeat domain targeting | ROC Domain Binding Assay (Need full-length LRRK2 with intact GTPase domain) |
| ASO / RNAi | Ionis Pharmaceuticals | Parkinson's Disease | Cellular validation (Need Lentivirus cell lines and siRNA controls) |
| Inhaled Formulation | Denali (preclinical) | Lung-targeted delivery (avoiding systemic exposure) | Stability Assay (Need high-concentration protein for nebulization compatibility testing) |
| Phenotypic Screening Tool | Global Pharma/CRO | Neurodegeneration | High-content Cell-based Assay (Need LRRK2 Lentivirus stable lines) |